新列线图预测初诊转移性前列腺癌的去势抵抗与生存结局
该研究回顾性分析449例初诊转移性前列腺癌患者,随机分为训练组314例和验证组135例,基于Gleason评分、导管内癌等6项因素构建预测去势抵抗性前列腺癌(CRPC)发生和总生存(OS)的列线图,内部验证C指数分别为0.762和0.723,并据此建立风险分层系统。
要点
- 列线图可预测初诊转移性前列腺癌的CRPC发生和OS,内部验证C指数分别为0.762和0.723。
- 导管内癌和Gleason评分是CRPC发生和OS的最强预后因素。
- 风险分层后中位至CRPC时间分别为62.6、28.0和13.0个月(P < 0.001)。
核心结论
- 开发了两个新列线图预测初诊转移性前列腺癌患者的CRPC发生率和OS,可能辅助医生决策和临床试验设计。
研究设计与样本
- 回顾性分析449例初诊转移性前列腺癌患者,随机分为训练组(n = 314,70%)和验证组(n = 135,30%)。
主要发现
- 预测因素包括Gleason评分、导管内癌、ECOG状态、碱性磷酸酶、血红蛋白和前列腺特异性抗原水平。
- 导管内癌和Gleason评分是CRPC发生和OS的最强预后因素。
- 预测CRPC和OS的列线图内部验证一致性指数分别为0.762和0.723。
- 根据最终模型的β系数构建风险分类系统,预后良好、中等和差的患者中位至CRPC时间分别为62.6、28.0和13.0个月(P < 0.001)。
- 中位OS分别为未达到、55.0和33.0个月(P < 0.001)。
关键数值与推荐
- 预测因素包括Gleason评分、导管内癌、ECOG状态、碱性磷酸酶、血红蛋白和前列腺特异性抗原水平。
- 列线图内部验证C指数:CRPC为0.762,OS为0.723。
- 风险分层中位至CRPC时间:良好62.6个月,中等28.0个月,差13.0个月(P < 0.001)。
- 风险分层中位OS:良好未达到,中等55.0个月,差33.0个月(P < 0.001)。
临床怎么用
- 列线图可用于预测初诊转移性前列腺癌患者的CRPC发生和OS,辅助医生决策和临床试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To develop nomograms predicting the incidence of castration-resistant prostate cancer (CRPC) and overall survival (OS) for de novo metastatic prostate cancer (PCa). PATIENTS AND METHODS: Data from 449 patients with de novo metastatic PCa were retrospectively analysed. Patients were randomly divided into a training (n = 314, 70%) and a validation cohort (n = 135, 30%). Predictive factors were selected using a Cox proportional hazards model and were further used for building predictive models. The outcomes were incidence of CRPC and OS. RESULTS: Predictive factors included: Gleason score (GS), intraductal carcinoma of the prostate (IDC-P), Eastern Cooperative Oncology Group status, and alkaline phosphatase, haemoglobin and prostate-specific antigen levels. IDC-P and GS were the strongest prognosticators for both the incidence of CRPC and OS. Nomograms for predicting CRPC and OS had an internal validated concordance index of 0.762 and 0.723, respectively. Based on the β coefficients of the final model, risk classification systems were constructed. For those with favourable, intermediate and poor prognosis, the median time to CRPC was 62.6, 28.0 and 13.0 months (P < 0.001), respectively; and the median OS was not reached, 55.0 and 33.0 months, respectively (P < 0.001). CONCLUSIONS: We developed two novel nomograms to predict the incidence of CRPC and OS for patients with de novo metastatic PCa. These tools may assist in physician decision-making and the designing of clinical trials.
引用
- Zhao J, Sun G, Liao B, et al. Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer. BJU Int. 2018. PMID: 29772102. doi:10.1111/bju.14398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。